Physician profile
Sheila D Smith
NPI 1487859708
$419.39
in general payments reported to CMS, 2019-2025
11 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.03 · 2023: $22.70 · 2024: $19.40 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $149.36 | 2025 | |
| Abbott Laboratories | $86.32 | 2025 | Infinity |
| Microtransponder, INC. | $53.62 | 2025 | |
| Boston Scientific Corporation | $23.30 | 2025 | Vercise |
| Acadia Pharmaceuticals INC | $22.70 | 2023 | Nuplazid |
| Genzyme Corporation | $20.12 | 2025 | |
| Ucb, INC. | $19.40 | 2024 | Fintepla |
| Emd Serono, INC. | $16.03 | 2022 | |
| Csl Behring | $14.69 | 2025 | Hizentra |
| Amgen INC. | $13.85 | 2025 | Uplizna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.